Covaxin: Already meets the continuous listing standards of the Nasdaq Global Market.
Kexing Biotech Co., Ltd. announced on June 15th that the company has received a notification from NASDAQ Listing Qualifications on June 10th, confirming that it is now in compliance with Rule 5250 and has met the continued listing standards of NASDAQ Global Market.
Latest

